Ftse Mib
34.657,35
0,93%
DAX
18.772,85
0,50%
S&P 500
5.222,68
0,16%
NASDAQ
16.340,87
-0,03%
Bitcoin
60.898,21
0,17%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Curis Inc (CRIS) Curis Inc (CRIS) Notizie

CRIS

Curis (CRIS)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CRIS
DataOraFonteTitoloSimboloCompagnia
10/05/202414:00PR Newswire (US)Curis to Present Updated Data from the TakeAim Leukemia StudyNASDAQ:CRISCuris Inc
07/05/202414:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CRISCuris Inc
07/05/202414:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CRISCuris Inc
07/05/202414:00PR Newswire (US)Curis Provides First Quarter 2024 Business UpdateNASDAQ:CRISCuris Inc
30/04/202414:00PR Newswire (US)Curis to Release First Quarter 2024 Financial Results and Hold Conference Call on May 7, 2024NASDAQ:CRISCuris Inc
05/04/202413:30PR Newswire (US)Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:CRISCuris Inc
04/04/202413:30PR Newswire (US)Curis to Present at Upcoming Healthcare Conferences in AprilNASDAQ:CRISCuris Inc
12/02/202422:16Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:CRISCuris Inc
08/02/202422:36Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:CRISCuris Inc
08/02/202422:27Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:CRISCuris Inc
08/02/202422:01Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:CRISCuris Inc
08/02/202414:00PR Newswire (US)Curis Provides Fourth Quarter 2023 Business UpdateNASDAQ:CRISCuris Inc
01/02/202414:00PR Newswire (US)Curis to Release Fourth Quarter 2023 Financial Results and Hold Conference Call on February 8, 2024NASDAQ:CRISCuris Inc
21/12/202322:00Edgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:CRISCuris Inc
12/12/202314:00PR Newswire (US)Curis Announces Initial Combination Study Data from its TakeAim Lymphoma StudyNASDAQ:CRISCuris Inc
11/12/202314:00PR Newswire (US)Curis Presented Clinical Data from the TakeAim Leukemia Study at the 2023 ASH ConferenceNASDAQ:CRISCuris Inc
06/12/202314:00PR Newswire (US)Curis Announces Three Presentations at ASHNASDAQ:CRISCuris Inc
05/12/202314:00PR Newswire (US)Curis Enters into Agreement for Emavusertib / Pembrolizumab Combination Study in MelanomaNASDAQ:CRISCuris Inc
02/11/202313:00PR Newswire (US)Curis Provides Third Quarter 2023 Business UpdateNASDAQ:CRISCuris Inc
26/10/202314:30PR Newswire (US)Curis to Release Third Quarter 2023 Financial Results and Hold Conference Call on November 2, 2023NASDAQ:CRISCuris Inc
28/09/202322:05Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:CRISCuris Inc
12/09/202314:00PR Newswire (US)Curis Announces Date for the 2nd Symposium on IRAK4 in CancerNASDAQ:CRISCuris Inc
06/09/202314:13PR Newswire (US)Curis to Present at Upcoming Healthcare Conferences in SeptemberNASDAQ:CRISCuris Inc
18/08/202322:02Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:CRISCuris Inc
04/08/202322:09Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:CRISCuris Inc
03/08/202322:01PR Newswire (US)Curis Provides Second Quarter 2023 Business UpdateNASDAQ:CRISCuris Inc
28/07/202300:25PR Newswire (US)Curis to Release Second Quarter 2023 Financial Results and Hold Conference Call on August 3, 2023NASDAQ:CRISCuris Inc
06/07/202322:30Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:CRISCuris Inc
06/07/202314:01PR Newswire (US)FDA Removes Partial Clinical Hold on TakeAim Leukemia Study RP2D Established at 300 mg BIDNASDAQ:CRISCuris Inc
06/07/202314:00PR Newswire (US)Curis Announces $15.1 Million Registered Direct OfferingNASDAQ:CRISCuris Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CRIS

La tua Cronologia

BIT
ENEL
Enel
BIT
UCG
Unicredit
BIT
BFF
BFF Bank
BIT
ISP
Intesa Sanpaolo
BIT
LDO
Leonardo
BIT
IVG
Iveco Group NV
BIT
RACE
Ferrari NV
BIT
STLAM
Stellantis NV
BIT
ENI
Eni
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
NEXI
Nexi S.p.A
BIT
BPE
Bper Banca
BIT
BAMI
Banco BPM
BIT
MB
Mediobanca Banca di Cred...
BIT
PRY
Prysmian
BIT
STMMI
ST Microelectronics
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network